Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inadvertent lung cancer screening results are discussed in a new study.

2.

Cancerous breast tissue glows in new AI-enhanced MRI images

3.

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

4.

Bayer is transforming pharmaceutical research into women's health

5.

Prostate cancer detection with PET CT and PET MRI is comparable.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot